Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Revelation Biosciences, Inc. - Common Stock (NQ:REVB)

0.8800 -1.0500 (-54.40%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Revelation Biosciences, Inc. - Common Stock

< Previous 1 2 Next >
Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients
From Revelation Biosciences, Inc.
Via Business Wire
Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025
From Revelation Biosciences Inc.
Via Business Wire
Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025
From Revelation Biosciences, Inc.
Via Business Wire
Nasdaq Grants Revelation Biosciences Inc. Continued Listing
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds
From Revelation Biosciences Inc.
Via Business Wire
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023
From Revelation Biosciences, Inc.
Via Business Wire
Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)
From Revelation Biosciences Inc.
Via Business Wire
Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference
From Revelation Biosciences Inc.
Via Business Wire
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini
From Revelation Biosciences Inc.
Via Business Wire
Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
From Revelation Biosciences Inc.
Via Business Wire
BioMedNewsBreaks – Revelation Biosciences Inc. (NASDAQ: REVB) Secures ~$6.2M in Public Offering
Via Investor Brand Network
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.